PD-1, the only PD-1 to enter the national health insurance system, sold more than $1.5 billion in three months this year

(2020/10/29) Up to $767 million Novaral has two partnerships on COVID-19 and pancreatic cancer therapy; DIP point method challenges private health care; step-by-point delivery of chemotherapy drugs: click on new chemical uses; will the smart case under DRG be the next wind... (Click on the title, available in the original article) Up to $767 million Novaral has launched two partnerships on COVID-19 and pancreatic cancer therapy, and Novarma and Zurich-based Molecular Partners AG have announced deals for two therapeutic candidates for the prevention and treatment of COVID-19 infections, MP0420 and MP0423.
same day, XOMA also announced that NIS793, a monoclonal antibody resistant to TGF beta, had been approved for Phase II clinical trials, triggering a $25 million milestone payment from Novarma.
: Swiss pharmaceutical giant Novarma has been working with outside companies in recent times.
PD-1, the only PD-1 to enter the national health insurance system, sold more than 1.5 billion yuan in three months this year, Xinda Bio announced that its PD-1 product Xindili monoanti-injection (commodity name Daboshu) received more than 600 million yuan in the third quarter of 2020. Sales results, coupled with previously announced first- and second-quarter revenue, Xindili achieved cumulative sales revenue of more than 1.5 billion yuan in the first three quarters, according to this quarter-by-quarter growth trend, its current year revenue is expected to exceed 2 billion yuan, compared with last year's annual sales of 1,015.9 million yuan, a full doubling.
headlines: Syndication monoanti is ushering in rapid market volume.
the smart case under drG be the next wind mouth? The case is the original record of the whole process of patient's diagnosis and treatment in the hospital, which reflects the quality of medical treatment and technical level, and is closely related to medical safety.
specifically, the importance of medical records for hospital medical quality control, teaching, scientific research, handling medical disputes, medical decision-making, the implementation of DRGs payment system, etc.
: A large number of CDSS companies have begun to cut into DRG from case quality control.
. Chinese medicine source: Click chemical new use Recently Shasqi company invented a click chemical new use, used to deliver chemotherapy drugs to tumor tissue.
the technology platform, called Click Activated Protodrugs Against Cancer (CAPAC), has two components, one is a water-soluble pre-drug injected directly into the tumor tissue hyaluracintic acid (NaHA) polypolymer derivative SQL70, and the other is a chemotherapy drug.
NaHA was added to a fragment called tetrate, while the chemotherapy drug was given a carbonate to a transcycline.
: Clicking on a chemical reaction to form a difficult carbon bond is less than it looks, but it's actually very useful.
The challenge of DIP point method to private medical treatment If DRG's challenge to private medical care is focused on the impact on inefficient and low-value business, then the challenge of DIP point method to private medical care is mainly focused on the scale of its own business.
, DIP's short-term impact on private medical care is greater than DRG's, and will be directly related to its own survival.
headlines: The challenge for private hospitals is unprecedented, as the DIP point method is being pushed forward.